Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit.
Montaudié H, Le Duff F, Butori C, Hofman V, Fontas E, Roger-Cruzel C, Bahadoran P, Perrot JL, Desmedt E, Legoupil D, Passeron T, Lacour JP. Montaudié H, et al. Among authors: legoupil d. J Am Acad Dermatol. 2020 Mar;82(3):731-733. doi: 10.1016/j.jaad.2019.07.035. Epub 2019 Jul 17. J Am Acad Dermatol. 2020. PMID: 31325551 Free article. Clinical Trial. No abstract available.
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C. Tétu P, et al. Among authors: legoupil d. Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22. Eur J Cancer. 2019. PMID: 30909072
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase. Vallet A, et al. Among authors: legoupil d. JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425. JAMA Dermatol. 2019. PMID: 31042256 Free PMC article.
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T. Brunot A, et al. Among authors: legoupil d. JAMA Dermatol. 2020 Sep 1;156(9):982-986. doi: 10.1001/jamadermatol.2020.2149. JAMA Dermatol. 2020. PMID: 32667663 Free PMC article.
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob JJ, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guégan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Lévy V; Groupe de Cancérologie Cutanée30. Maubec E, et al. Among authors: legoupil d. J Clin Oncol. 2020 Sep 10;38(26):3051-3061. doi: 10.1200/JCO.19.03357. Epub 2020 Jul 30. J Clin Oncol. 2020. PMID: 32730186 Clinical Trial.
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆.
Di Filippo Y, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Beylot-Barry M, Stoebner PE, Dupuy A, Stephan A, Grob JJ, Lefevre W, Oriano B, Allayous C, Lebbé C, Montaudié H. Di Filippo Y, et al. Among authors: legoupil d. Ann Oncol. 2021 Apr;32(4):542-551. doi: 10.1016/j.annonc.2020.12.012. Epub 2020 Dec 30. Ann Oncol. 2021. PMID: 33385520 Free article.
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.
Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudié H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le-Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C. Carlet C, et al. Among authors: legoupil d. J Am Acad Dermatol. 2022 Feb;86(2):345-352. doi: 10.1016/j.jaad.2021.06.849. Epub 2021 Jun 18. J Am Acad Dermatol. 2022. PMID: 34153388
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, Lebbe C. Plaçais L, et al. Among authors: legoupil d. Ann Rheum Dis. 2022 Oct;81(10):1445-1452. doi: 10.1136/ard-2022-222186. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788496 Free article.
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Girod M, Dalle S, Mortier L, Dalac S, Leccia MT, Dutriaux C, Montaudié H, de Quatrebarbes J, Lesimple T, Brunet-Possenti F, Saiag P, Maubec E, Legoupil D, Stoebner PE, Arnault JP, Lefevre W, Lebbe C, Dereure O. Girod M, et al. Among authors: legoupil d. JCO Precis Oncol. 2022 Nov;6:e2200075. doi: 10.1200/PO.22.00075. JCO Precis Oncol. 2022. PMID: 36356284
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Brunet-Possenti F, De Quatrebarbes J, Grob JJ, Saiag P, Maubec E, Stoebner PE, Granel-Brocard F, Arnault JP, Allayous C, Oriano B, Lebbe C, Montaudié H. Rousset P, et al. Among authors: legoupil d. J Am Acad Dermatol. 2023 Apr;88(4):808-815. doi: 10.1016/j.jaad.2022.11.040. Epub 2022 Dec 19. J Am Acad Dermatol. 2023. PMID: 36543626
39 results